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Abstract
Background: Notch and TLR pathways were found to act cooperatively to activate Notch target genes and to
increase the production of TLR-induced cytokines in macrophages. However, the mechanism of LPS-induced Notch
activation and its role in sepsis still remains unclear.
Methods: We analyzed the expression patterns of Notch components in a LPS-stimulated murine macrophage cell
line using real-time PCR and western blotting. The role of DAPT, a gamma-secretase inhibitor that is known to be a
potent Notch inhibitor, in LPS-induced cytokine release and experimental sepsis in mice was also explored.
Student’s t-test was used to analyze the difference between the two groups.
Results: We found that Notch signaling was activated after LPS stimulation. The expression of Jagged 1, a Notch
ligand, induced by LPS occurred in a JNK-dependent manner. In addition, Notch target genes were upregulated by
early Notch-independent activation followed by delayed Notch-dependent activation after LPS stimulation.
Disruption of Notch signaling by DAPT attenuated the LPS-induced inflammatory responses, including vascular
endothelial growth factor (VEGF) and high-mobility group box chromosomal protein 1 (HMGB1), both in vitro and
in vivo and partially improved experimental sepsis survival.
Conclusions: These findings support the existence of a synergistic effect of Notch signaling and the LPS pathway
both in vitro and in vivo. Therefore, in the future Notch inhibitors may be utilized as adjunctive agents for the
treatment of sepsis syndrome.
Background
Sepsis is a lethal infection-induced systemic inflamma-
tory syndrome and organ dysfunction triggered by bac-
teria or bacterial products. Sepsis-related mortality is a
leading cause of death and is increasing worldwide
[1-5]. An overwhelming systemic inflammatory response
is the most frequent pathological picture associated with
sepsis and leads to fatal multiple organ failure [6,7].
Many basic and clinical studies have focused on target-
ing proinflammatory mediators implicated in the patho-
physiology of sepsis. Unfortunately, most clinical trials
so far have not led to an improved overall outcome for
persons with this serious medical condition [6-11].
Notch signaling is a highly conserved pathway
involved in cell fate decisions, proliferation, and survival
[12]. In mammalians, there are four Notch receptors
(Notch-1 to -4) and five Notch ligands (Delta-like-1, -3,
and -4 and Jagged-1 and -2). Notch-ligand binding leads
to the shedding of the Notch extracellular domain and
subsequent release of the Notch intracellular domain
(NICD) by a g-secretase complex. The NICD is translo-
cated to the nucleus, where it binds to the transcription
factor Rbp-jk and results in the activation of Notch
downstream target genes such as basic helix-loop-helix
family (Hes1 and Hes5) and hairy and enhancer of split-
related (HESR) family (Hey1 and Hey2) [13]. * Correspondence: tsaopn@ntu.edu.tw
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the development and function of macrophages, NK
cells, T cells, B cells, and dendritic cells has been
reported [14-18]. Upon infection, Toll-like receptor
(TLR) ligands activate macrophages resulting in the pro-
duction of inflammatory cytokines such as TNF-a,
interleukin-1b (IL-1b), and IL-6 [19]. Several Notch
receptors and ligands are expressed in both human and
mouse macrophages [14,20,21]. Recently, Notch and
TLR pathways were found to act cooperatively to acti-
vate Notch target genes and to increase the production
of TLR-induced cytokines in macrophages [14,22,23]. In
addition, some reports also indicated that Notch signal-
ing plays an important role in inflammatory disorders
[24,25]. This data allowed us to hypothesize that Notch
signaling may play a role in the pathogenesis of sepsis.
Here we report that Notch pathway components are
expressed in murine macrophages. LPS-induced Jagged1
(Jag1) was expressed in a JNK-dependent manner. By
using loss-of-function and gain-of-function models in
vitro, we demonstrate that Notch signaling amplifies the
production of LPS-induced inflammatory cytokines
including the free form of vascular endothelial growth
factor (VEGF) by attenuating the secretion of soluble
Flt-1 (sFlt-1). Finally, pharmacological inhibition of
Notch activation attenuates the endotoxemia response
and partially improves the survival rate of experimental
sepsis. We conclude that activation of the Notch path-
way in macrophages is important in the development of
sepsis and could represent a new adjuvant therapy.
Materials and methods
Cell culture and reagents
Murine macrophage-like RAW 264.7 cells were
obtained from the American Type Culture Collection
(Manassas, VA, USA) and cultured in DMEM (Gibco
BRL, Grand Island, NY, USA) supplemented with 10%
fetal bovine serum and 4 mM glutamine. Cells were
c u l t u r e di nt h ep r e s e n c eo fL P S( f r o mEscherichia coli
0111:B4; Sigma-Aldrich, SL, USA) with or without a
Notch inhibitor or activator (see below). Specific
MAPK inhibitors, PD98059 (Sigma-Aldrich, SL, USA),
SB203580 and SP600125 (both from Calbiochem, CA,
USA) were used at the concentrations indicated in the
figure legends.
Animals
The animal protocol was approved by the Animal Care
and Use Committee of the National Taiwan University
Hospital. C56BL/6 strain mice were obtained from the
Animal Center of the College of Medicine, National Tai-
wan University. The animal room was kept on a 12-
hour light/dark cycle with temperature and humidity
held constant.
Endotoxemia
Endotoxemia was induced by an i.p. injection of LPS at
ad o s eo f5μg/g in PBS. We subjected mice to control
(vehicle alone) or to N-[ N-(3,5-difluorophenacetyl)-L-
alanyl]-(S)-phenylglycine-t-butyl ester (DAPT) (100 mg/
kg, Sigma-Aldrich, SL, USA). Plasma or tissues were col-
lected at indicated times.
Cecal ligation and puncture (CLP)
We performed CLP as described [26]. Briefly, we anesthe-
tized the mice with pentobarbital (50 mg/kg, i.p.). Under
sterile conditions, a 1-2 cm incision was made in the mid-
dle abdomen, and the cecum was exposed. We placed a
3 . 0s i l ks u t u r e5 . 0m mf r o mt h ec e c a lt i pa w a yf r o mt h e
ileocecal valve, punctured through twice with a 23-gauge
needle, and extruded a small amount of bowel contents (1
mm). We then placed the cecum back and closed the
abdominal cavity with a running suture with 3.0 silk. Mice
were resuscitated with 1 ml of saline s.c. and placed on a
heating pad until they recovered from the anesthetic. We
subjected the mice to vehicle and DAPT treatment and
m o n i t o r e dt h e mf o rs u r v i v a l .
Inhibition or activation of Notch signaling in vitro and in
vivo
To inhibit Notch signaling in vitro, RAW 264.7 cells
were treated with DMSO (1 μM) or two different g-
secretase inhibitors (GSIs): DAPT (10 μM) or JLK6 (1
μM, Calbiochem, CA, USA). To activate Notch signal-
ing, we added recombinant soluble Jag1, Dll1, or Dll4
(all from R & D Systems, MN, USA) in medium to a
final concentration of 1 μg/ml. To block Notch signaling
in vivo, DAPT was dissolved in corn oil containing 10%
ethanol, and DAPT (100 mg/kg) or vehicle (10 ml/kg)
was subcutaneously administered to endotoxemic mice
3 hours before LPS (15 μg/g) injection or to CLP mice 3
hours before and 24 hours after CLP.
Quantitative real-time PCR
Total RNA from cells and tissues was isolated using Tri-
zol. (Invitrogen, CA, USA) For reverse transcription, 2
μg of total RNA were transcribed using the iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Real-
time RT-PCR was performed using the DNA Engine
Opticon 2 detection system (Bio-Rad, CA, USA) and the
iQ SYBR Green supermix (Bio-Rad, CA, USA). The
threshold cycle (CT) values were obtained and the rela-
tive concentration of RNA for each gene to GAPDH
mRNA was determined using the equation: 2
-ΔCT, where
ΔCT=( CTmRNA-CTGAPDHmRNA).
Western blotting
Western blot analyses of MAPK pathways, NICD, and
high-mobility group box chromosomal protein 1
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50 μg of total cell lysate was separated on a 10% SDS-
polyacrylamide gel and transferred to a BioTrace PVDF
membrane (Pall Corporation, East Hills, NY, USA). The
blots were then blocked with 5% milk for 1 hour at
room temperature and probed with antibodies for
Jagged-1 (Santa Cruz Biotechnology Inc, Santa Cruz,
CA, USA), phospho (Thr202/Tyr204) and total ERK1/2,
phospho (Thr183/Tyr185) and total c-Jun N-terminal
kinase (Jnk), phospho (Thr180/Tyr182) and total p38,
cleaved Notch1 (all from Cell Signaling Technology Inc.,
Danvers, MA, USA), HMGB1 (BD Biosciences, NJ,
USA), and mouse actin (Sigma-Aldrich, SL, USA) at 4°C
overnight. ECL Plus reagents (Amersham Biosciences,
Sweden) and appropriate secondary antibodies (Bio-Rad,
CA, USA) were used for the detection of western blots.
Quantification of bands of the western blots was per-
formed using Image Lab (Bio-Rad Laboratory).
Measurement of cytokines, VEGF, and sFlt-1 levels
For measurement of LPS-induced cytokines in condi-
tioned medium and plasma, we collected conditional
medium and plasma at various times. Concentrations of
TNF-a,I L - 1 b, IL-6, the free form of VEGF, and sFlt-1
in samples were determined using ELISA kits (R & D,
MN, USA). All experiments were performed in tripli-
cate, and the data is expressed as mean ± SEM.
Statistical analysis
All data is expressed as mean ± SEM. Statistical analysis
was performed using SPSS 12.0 for Windows (Statistical
Package for Social Sciences, Inc., Chicago, IL, USA).
The Student’s t-test was used to analyze the difference
between the study and control groups; p values less
than 0.05 were considered statistically significant.
Results
Notch pathway components are present in murine
macrophages and activated by LPS stimulation
To identify the Notch pathway components in murine
macrophages, we measured their expressions in RAW
264.7 cells using real-timeP C R .W ef o u n dt h a tm u r i n e
macrophages constitutively expressed almost all Notch
receptors and ligands, although the levels of Notch3,
Dll3, and Hes1 were very low compared to Notch1 (Fig-
ure 1A). The most abundant Notch components
Figure 1 Expression of Notch pathway components in murine macrophages. (A) Expression levels of Notch receptors and ligands in RAW
264.7 cells relative to Notch1 expression. Transcript levels were determined by real-time PCR and normalized to GAPDH. (B) Expression levels of
Notch receptors and ligands with or without LPS stimulation (1 μg/ml) for 3 hours. Levels of the control group were set as 1. (C) The g-secretase
inhibitor DAPT (10 μM) did not prevent LPS-induced Hes5 and Hey2 expression. (D, E) LPS induced the formation of NICD in both dose- and
time-dependent manners. (), fold change as compared to basal level; *, P < 0.05.
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Notch1, Notch2, and Jag1 (Figure 1A).
Next, we asked whether LPS can activate Notch sig-
naling. We found that the levels of Notch1, Jag1, Hes5,
and Hey2 were significantly increased at 3 hours after
LPS stimulation as compared to levels in unstimulated
cells (Figure 1B). Surprisingly, disruption of Notch sig-
naling by a g-secretase inhibitor did not prevent this
early phase of LPS-induced Hes5 and Hey2 expression
(Figure 1C). In addition, we found that the Notch1
intracellular domain (NICD), the activated form of
Notch1, was not induced by LPS at 3 hours after stimu-
lation. However, its expression was increased at 6 hours
after LPS stimulation (Figure 1D). The stimulatory effect
of LPS (10-1000 ng/ml) on the production of NICD in
macrophages was found to be dose-dependent at 24
hours after stimulation (Figure 1E).
Activation of JNK is required for LPS-induced Jag1
expression
To understand the mechanism underlying the activation
of Notch signaling by LPS, we first examined the tem-
poral expression of Jag1,a st h i sl i g a n dw a sr o b u s t l y
induced Notch pathway component by LPS stimulation.
We found that Jag1 was significantly upregulated (about
4.5-fold) in macrophages at 2 hours after LPS stimula-
tion (Figure 2A). In addition, LPS also activated all three
MAPK pathways within 15 minutes (Figure 2B). To
investigate whether LPS-induced activation of MAPK
pathways is required for LPS-induced Jag1 expression,
we pretreated cells with specific MAPK inhibitors 30
minutes before LPS stimulation. We found that
SP600125 (SP; c-jun NH2-terminal kinase (JNK) inhibi-
tor), but not PD 98059 (PD; ERK inhibitor) or SB203580
(SB; p38 MPAK inhibitor), completely blocked LPS-
induced Jag1 expression (Figure 2C&D). These results
indicate that LPS-induced Jag1 expression is JNK-
dependent.
DAPT attenuated the production of LPS-induced
cytokines through blocking Notch signaling
To test whether Notch signaling is required for LPS-
induced secretion of cytokines in vitro, we investigated
the cytokine response in LPS-stimulated mouse macro-
phage RAW 264.7 cells by inhibiting g-secretase with
DAPT. Treatment of murine macrophages with DAPT
did not lead to increased cell death as measured by an
MTS assay (data not shown). In the absence of DAPT,
the levels of TNF-a,I L - 1 b, and IL-6 in conditioned
medium significantly increased at 6 hours after LPS sti-
mulation. The addition of DAPT partially, but signifi-
cantly, attenuated the LPS-induced increase in the levels
of released IL-1b and IL-6 (35% and 20% reduction,
respectively), but did not alter the level of TNF-a
(Figure 3A-C). As indicated in our previous report [26],
the level of soluble Flt-1 (sFlt-1), an anti-inflammatory
factor, in conditioned medium increased progressively
between 6 and 48 hours after LPS stimulation. DAPT
treatment significantly increased the sFlt-1 levels
induced by LPS (Figure 3D). In contrast, the level of the
free form of vascular endothelial growth factor (VEGF)
significantly decreased upon DAPT pretreatment to 70%
of that of the control group at 48 hours after LPS stimu-
lation (Figure 3E). We also measured the LPS-induced
secretion of the late mediator, extracellular HMGB1, in
conditioned medium using western blotting. Cytosolic
and extracellular HMGB1 levels were increased 2- and
1.5-fold, respectively, at 24 hours after LPS stimulation.
Interestingly, DAPT pretreatment significantly attenu-
ated the LPS-induced secretion of extracellular HMGB1
into conditioned medium, but did not change the LPS-
induced cytosolic HMGB1 expression (Figure 3F).
To test the specificity of the DAPT effect on Notch
signaling inhibition, we used JLK6, another g-secretase
inhibitor which cannot prevent NICD formation, instead
of DAPT under the same experimental conditions. Our
Figure 2 JNK activation is required for LPS-induced Jag1
expression in macrophages. (A) Time course of LPS-induced
expression of Jag1 protein. (), fold change as compared to basal
level (B) MAPK signal pathways were activated by LPS stimulation in
macrophages. (C) Cells were pretreated with 10 μM PD98059 (PD), 2
μM SB203580 (SB), 50 μM SP600125 (SP), or DMSO (D) as control 30
minutes before LPS stimulation, respectively. LPS-induced Jag1
expression was completely blocked by SP600125, a JNK inhibitor. (D)
Relative levels of Jag1 protein were determined by densitometry (n
= 3). The results represent the mean ± SD of three independent
experiments. *, P < 0.05 compared to control; #, P < 0.05 compared
to LPS only.
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cytokine production (data not shown). Taken together,
our results indicate that DAPT attenuated the produc-
tion of LPS-induced cytokines by blocking Notch
signaling.
Activation of notch signaling by soluble notch ligands
amplifies cytokine production in LPS-stimulated
macrophages
To further confirm the interplay between Notch signal-
ing and LPS and their synergistic effect on the induction
of proinflammatory cytokines in murine macrophages,
we measured the levels of IL-1b and IL-6 in conditioned
medium at 6 hours after stimulation with LPS with or
without the further addition of soluble Notch ligands.
By using real-time PCR, we found that treatment with
exogenous soluble Jag1, Dll1, or Dll4 resulted in modest
upregulation of Hey2 expression (Figure 4A-C). Further-
more, Jag1 significantly upregulated Hes5 (Figure 4A);
the higher mRNA level determined for Hes5 at treat-
ment with Dll1 does not appear to be statistically signifi-
cant (Figure 4B). Interestingly, D114 had no effect on
Hes5 (Figure 4C). In addition, the level of NICD was
modestly increased in Jag1- or Dll1-treated macrophages
(Figure 4D). This data shows that the treatment of mur-
ine macrophages with exogenous Notch ligands, espe-
cially Jag1 or Dll1, can further engage Notch receptors,
resulting in enhanced Notch activation in LPS-treated
macrophages.
Next, we measured the levels of IL-1b and IL-6 in
conditioned medium using ELISA. We found that solu-
ble Dll1 significantly amplified the LPS-induced secre-
tions of both IL-1b and IL-6 (Figure 4E, F). Soluble Jag1
had a similar effect (data not shown). The effects by
Dll1 and Jag1 can be rescued by DAPT (data not
shown). However, activating Notch signaling by soluble
Dll1 without LPS did not induce IL-1b or IL-6 secretion
in murine macrophages. This data further supports the
notion that Notch signaling synergizes with the LPS
pathway to stimulate the production of proinflammatory
cytokines.
Blocking notch signaling attenuates LPS-induced
inflammatory cytokine production in vivo
To determine the contribution of endogenously acti-
vated Notch signaling to inflammatory cytokine
Figure 3 DAPT inhibited Notch signaling and attenuated LPS-induced inflammatory responses.D A P T( 1 0μM) attenuated IL-1b (B), IL-6
(C), but not TNF-a (A) secretion in conditioned medium 6 hours after LPS (1 μg/ml) stimulation. DAPT also amplified the LPS-induced sFlt-1 (D),
an anti-inflammatory factor, and attenuated VEGF (E) secretion in a relatively late phase. (F) DAPT, indeed, prevented LPS-induced NICD
formation and inhibited HMGB1 secretion, but not production in macrophages 24 hours after LPS stimulation. (), fold change as compared to
basal level; *, P < 0.05.
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TNF-a,I L - 1 b, IL-6, sFlt-1, and VEGF in mice injected
with LPS (5 mg/kg) with or without DAPT pretreat-
ment. While the peak levels of IL-1b and IL-6 were sig-
nificantly decreased (55% and 30%) in the DAPT-treated
group, the peak levels of TNF-a were only slightly
reduced as compared to the LPS-only group (Figure 5A-
C). In addition, the plasma sFlt-1 levels significantly
increased in the presence of DAPT, resulting in a 33%
decrease of free VEGF levels (Figure 5D) in DAPT-/
LPS-treated mice. Furthermore, DAPT pretreatment
attenuated the LPS- NICD production of NICD and
HMGB1 (Figure 5E).
Finally, to study whether blockage of Notch signaling
by DAPT protects against lethality in experimental sep-
sis, we performed LPS-induced endotoxemia and CLP
experiments on mice with or without DAPT pretreat-
ment. However, we found that DAPT treatment only
partially improved the survival rate of CLP-induced leth-
ality from 70% in the absence of DAPT to 90% with pre-
treatment (Figure 5F).
Discussion
The present study supports our hypothesis that the
Notch pathway orchestrates LPS signaling in macro-
phages and experimental sepsis. Our data demonstrates
that LPS-induced Notch activation occurs in a dose-
and time-dependent manner in macrophages. By using a
pharmacological approach to add exogenous soluble
ligands to activate Notch signaling, we showed that
LPS-induced Notch activation amplifies the inflamma-
tory response to LPS stimulation in macrophages.
Finally, we demonstrated a partially protective effect of a
Notch signaling inhibitor in experimental sepsis.
Several studies have shown that Notch signaling com-
ponents exist in both human and murine macrophages
[14,20,21,23], although their expression patterns were
different among different species. Jag1-Notch1 signaling
regulated gene expression in activated macrophages has
also been shown [20,21]. Here, we demonstrated that
not only Jag1, but also Dll1 can increase the activation
of Notch1 and increase the expression of Hes5 and
Hey2 induced by LPS stimulation. However, in contrast
to data reported with human macrophages [14], we
found that Dll4 has no or only a small effect on LPS-
induced Notch activation in murine macrophages. This
discrepancy may be due to the fact that macrophages of
different species were examined. In addition, our data
showed that Jag1, Dll1 and Dll4 have differential effects
on the expression of Notch target genes after LPS sti-
mulation. Further studies are needed to address this
issue.
Recently, Hu et al. showed that LPS stimulation
directly induced the expression of the canonical Notch
target genes Hes1 and Hey1 without increasing the
expression of NICD or Notch ligands within 1-6 hours
of stimulation in human primary macrophages [23].
However, the mechanism of induction is still unclear. In
this study, we found that the canonical Notch target
g e n e sH e s 5a n dH e y 2 ,a sw e l la sN o t c hr e c e p t o r sa n d
ligands were upregulated within 3 hours after LPS sti-
mulation. However, during the first 3 hours of LPS sti-
mulation, no obvious increase in the expression of
NICD was found. In addition, disruption of Notch sig-
naling by the g-secretase inhibitor DAPT did not pre-
vent LPS-induced Hes5 and Hey2 expression at 3 hours
after LPS stimulation. This data suggests that LPS-
induced expression of Notch target genes consists of an
immediate-early Notch-independent activation and is
followed by a delayed, indirect Notch-dependent
activation.
Strikingly, Jag1 was rapidly induced by LPS stimula-
tion in murine macrophages. By using a pharmacological
approach, we clearly demonstrated that LPS-induced
Jag1 expression is mediated by a JNK-dependent
Figure 4 Soluble Notch ligands activated Notch signaling and
amplified LPS-induced inflammatory responses. (A) Soluble
Jagged1 (sJag1; 1 μg/ml) augmented LPS-induced Hes5 and Hey2
mRNA expression in macrophages. sDll1 (B) and sDll4 (C) also had a
similar effect. (D) sJag1, sDll1, and sDll4, especially sDll1 (all 1 μg/ml),
significantly enhanced LPS-induced NICD formation. (), fold change
as compared to basal level. sDll1 significantly amplified LPS-induced
IL-1b (E) and IL-6 (F) secretion in macrophages. *, P < 0.05.
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results demonstrating that Jag1 is a direct target of TLR
signaling and that the induction of Jag1 expression is
partially dependent on canonical TLR-activated NF-kB
and MAPK signaling pathways [22].
What is the role of Notch signaling in LPS-induced
inflammatory responses? We demonstrated that DAPT
significantly attenuated the secretion of intermediate
(IL-1b and IL-6) and late inflammatory cytokines
(VEGF and HMGB1), but not of an early inflammatory
cytokine (TNF-a). This result is reasonable because
DAPT can only prevent the cytokine response at 3
hours after LPS-induced Notch activation. However,
the effect of Notch inhibition on LPS-induced proin-
flammatory cytokines was modest. In contrast, JNK6, a
GSI that does not influence Notch activity, has no
anti-inflammatory effect. Furthermore, the activation of
Notch signaling by exogenous Notch ligands has the
opposite effect on the production of LPS-induced
proinflammatory cytokines. Together with this data,
this suggests that DAPT specifically inhibits LPS-
induced Notch activation followed by attenuating the
inflammatory responses.
Another interesting finding is that DAPT increased
sFlt-1 secretion and decreased VEGF secretion in LPS-
treated macrophages. Previously, we and others reported
the protective effect of sFlt-1 through inhibiting VEGF
signaling in experimental sepsis [26,28]. In this study,
we observed a continuous increase in sFlt-1 secretion
from 6 to 48 hours after LPS stimulation. By contrast,
VEGF secretion induced by LPS was attenuated until 48
hours after LPS stimulation. This data suggests that the
reduced levels of the free form of VEGF, an inflamma-
tory cytokine, was a consequence of the increased levels
of sFlt-1 as its binding to VEGF decreases the free form
of VEGF [29]. To the best of our knowledge, our study
is the first report demonstrating that a disruption of
LPS-induced Notch activation can amplify the effect of
LPS-induced sFlt-1 secretion and modulate VEGF
activity.
Finally, the protective effect of DAPT treatment in
vivo is moderate in this study. There are some possibili-
ties to explain this result: (1) the dose of DAPT or the
timing of treatment may not be optimal considering the
relatively short half-life of DAPT [30]; (2) DAPT only
has a partial effect on attenuating LPS-induced
Figure 5 Protective effect of DAPT against endotoxemia and experimental sepsis. Pretreatment with DAPT (100 mg/kg) dissolved in corn
oil attenuated a sublethal dose of LPS (5 μg/kg) induced TNF-a (A), IL-1b (B), and IL-6 (C) secretion in plasma. (D) LPS-induced sFlt-1 secretion
was enhanced by DAPT treatment which resulted in decreased plasma free form VEGF levels. (E) DAPT pretreatment decreased LPS-induced
HMGB1 expression in liver tissues. (), fold change as compared to basal level (F) Pretreatment with DAPT partially protected mice from CLP-
induced lethality (n = 10 mice per group). *, P < 0.05.
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vitro experiments; (3) the Notch signaling network is
more complicated in vivo than in vitro, so a GSI only
has a partially protective effect in vivo. However, using a
genetic approach, Hu et al. demonstrated that deletion
of RBP-J in the myeloid compartment protected mice
from endotoxin lethality in vivo [23]. In addition, we
also showed that blocking Notch signaling by DAPT
injection attenuated LPS-induced inflammatory cytokine
production in vivo (Figure 5). This data suggests that
modulation of Notch signaling by a g-secretase inhibitor
might be an adjuvant pharmacologic strategy to improve
the treatment of sepsis.
Conclusions
In summary, we demonstrated that Notch target genes
can be induced by LPS in both Notch-independent and
Notch-dependent manners. The LPS-induced intermedi-
ate and late inflammatory responses were attenuated by
the g-secretase inhibitor DAPT and amplified by soluble
Notch ligands in vitro. Furthermore, we demonstrated
that DAPT has a partially protective effect on experi-
mental sepsis in vivo. Our data therefore suggest that a
Notch inhibitor holds potential as an adjunctive agent
for the treatment of sepsis syndrome.
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